| Catalog No. | HB651086 |
|---|
| Species reactivity | Human |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Host species | Humanized |
|---|
| Isotype | [V-kappa’-VH-h-CH2-CH3_V-kappa-VH’]2 |
|---|
| Expression system | Mammalian Cells |
|---|
| Clonality | Monoclonal |
|---|
| Target | CD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4, Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279 |
|---|
| Endotoxin level | Please contact the lab for this information. |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Accession | P16410 & Q15116 |
|---|
| Form | Liquid |
|---|
| Storage buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Alternate Names | TetravalentBispecific, MGD019, MGD-019, MGD0192416595-46-3 |
|---|
| Background | Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting antibody (DART). Lorigerlimab can block PD-1 and CTLA-4, and improves T-cell responses. Lorigerlimab can be used for research of metastatic castration-resistant prostate cancer (mCRPC).
• Cancer immunotherapy using checkpoint blockade., PMID:29567705
• The blockade of immune checkpoints in cancer immunotherapy., PMID:22437870
• Immune-related adverse events of checkpoint inhibitors., PMID:32382051
• Immune Checkpoint Blockade in Cancer Therapy., PMID:25605845
• Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy., PMID:29256113
• Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination., PMID:27141885
• Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints., PMID:30184160
• Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review., PMID:28945858
• Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer., PMID:34088360
• Fundamental Mechanisms of Immune Checkpoint Blockade Therapy., PMID:30115704
|
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|
